Microbiotica enters into microbiome collaboration with Genentech

Sanger Institute spin out company signs strategic collaboration to apply its leading microbiome Reference Genome Database and Culture Collection to discover microbiome biomarker signatures and therapeutic targets for inflammatory bowel disease

Microbiotica enters into microbiome collaboration with Genentech

Sanger Institute spin-out company Microbiotica

Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today (6 June 2018) announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD).

Under the terms of the agreement, Microbiotica will utilise its precision metagenomics microbiome platform to analyse patient samples from clinical trials of Genentech’s investigational IBD medicines, in order to identify microbiome biomarker signatures of drug response, novel IBD drug targets and live bacterial therapeutic products. Microbiotica will receive an undisclosed upfront payment and is eligible to receive research, development and commercialisation milestone payments up to $534 million based on achievement of certain predetermined milestones. In addition, Microbiotica is eligible to receive royalties on sales of certain products resulting from the collaboration. Genentech also has an option to license assets that Microbiotica develops as a result of the research collaboration.

Microbiotica was formed 18 months ago with funding from Cambridge Innovation Capital and IP Group to commercialise ground-breaking microbiome science at the Wellcome Trust Sanger Institute, from the laboratory of Dr Trevor Lawley, CSO of Microbiotica.

The Microbiotica platform comprises the world’s leading microbiome Culture Collection and linked Reference Genome Database that enable unprecedented precision of gut bacterial identification at clinical trial scale. The Company is adding to this at a very rapid rate through its industrial culturing and sequencing pipeline, providing the best available representation of clinical trial samples for strain-level identification of bacteria. The complex datasets that arise from such studies are analysed using AI techniques to discern microbiome signatures linked to phenotype. The availability of the physical Culture Collection enables biological evaluation of bacteria in proprietary translational models including humanised microbiome mouse models.

“This collaboration brings together a world-class pipeline of investigational IBD medicines from Genentech with the world-class microbiome capability of Microbiotica. We are excited by the opportunity to work with Genentech scientists in order to bring precision metagenomics into the clinical arena for the first time, enabling us to develop biomarkers and medicines for the benefit of patients.”

“This collaboration reflects Microbiotica’s strategy of utilising its platform for medicines and biomarker discovery while simultaneously expanding platform capabilities. Whilst Genentech will retain rights to proprietary biomarkers, targets and medicines, the collaboration will enable Microbiotica to continue to rapidly expand its already leading Reference Genome Database and Culture Collection, further strengthening its value across all therapeutic areas.”

Dr Mike Romanos, CEO of Microbiotica

“We believe the microbiome represents a new paradigm in biomedicine, both for understanding drug response and as a novel therapeutic modality. We have chosen to collaborate with Microbiotica because of its high-quality science and look forward to working together to potentially bring new medicines to people suffering from IBD.”

James Sabry, M.D., Ph.D., Senior Vice President and Global Head of Genentech Partnering

Notes to Editors
About the Microbiome

Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.

Selected Websites
Life in the Lab: working with human gut microbiotaVideoLife in the Lab: working with human gut microbiota
This film shows how lab scientists work safely with human gut bacteria; culturing them on agar plates and extracting DNA for genome sequencing.

Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Human Cell Atlas gets a boost with first funding from Wellcome

Injection of £7 million will help to create a cellular 'Google map' of the human body, which could revolutionise health and disease

Kidney cancer's developmental source revealed

Study reveals that kidney cancers may arise from cells that haven't fully developed, offering a new target for treatment

Explore nature's genetic secrets in new exhibition

Curious Nature exhibition explores the Wellcome Sanger Institute’s 25th anniversary project to sequence the genomes of 25 UK species for the first time.